EZH2 and Hyperglycemia: This work, albeit important as a proof-of-concept study but also recognizing its limitations, will require evaluation in a suitable diabetic animal model to determine whether the functional response to glucose by inhibiting pancreatic EZH2 is capable of ameliorating hyperglycaemia through a duct-to-β-cell regenerative pathway.